Effect of nadroparin, a low-molecular-weight heparin, on clinical and angiographic restenosis after coronary balloon angioplasty: The FACT study

Circulation

Volumn 96, Issue 10, 1997, Pages 3396-3402

  Lablanche, Jean Marc ⁱ   McFadden, Eugène P ^j   Meneveau, Nicolas ^j   Lusson, Jean René ^j   Bertrand, Bernard ^a   Metzger, Jean Philippe ^b   Legrand, Victor ^j   Grollier, Gilles ^c   Macaya, Carlos ^d   De Bruyne, Bernard ^e   Vahanian, Alec ^j   Grentzinger, Alain ^j   Masquet, Christiane ^f   Wolf, Jean Eric ^g   Tobelem, Gerard ^f   Fontecave, Sylvie ^h   Vacheron, André ^j   D'Azemar, Pascal ^h   Bertrand, Michel E ^j  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c CAEN UNIVERSITY HOSPITAL   (France)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^e OLV HOSPITAL   (Belgium)

^f HÔPITAL LARIBOISIÈRE   (France)

^g DIJON UNIVERSITY HOSPITAL   (France)

^h SANOFI   (France)

ⁱ LILLE UNIVERSITY HOSPITAL   (France)

^j NONE

more..

Author keywords

Angioplasty; Anticoagulants; Aspirin; Heparin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO;

ADULT; AGED; ARTERY INJURY; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEMATOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA;

EID: 0030812535     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.96.10.3396     Document Type: Article

References (19)

1. Liu MW, Roubin GS, King SB III. Restenosis after coronary angioplasty: potential biological determinants and role of intimai hyperplasia. Circulation. 1989;79:1374-1387.
2. Mintz GS, Popma JJ, Pichard AD, Kent KM, Satler LF, Wong C, Hong MK, Kovach JA, Leon MB. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation. 1996;94:35-43.
3. Clowes AW, Karnowsky MJ. Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature. 1977;265: 625-626.
4. Castellot JJ Jr, Addonizio ML, Rosenberg R, Karnovsky MJ. Cultured endothelial cells produce a heparin-like inhibitor of smooth muscle cell growth. J Cell Biol. 1981;90:372-377.
5. Reilly CF, Fritze LMS, Rosenberg RD. Heparin inhibition of smooth muscle cell proliferation: a cellular site of action. J Cell Physiol. 1986;129:11-19.
6. Fareed J. Development of heparin fractions: some overlooked considerations. Semin Thromb Hemost. 1985;11:227-236.
7. Harenberg J, Wuerzner B, Zimmermann R. Bioavailability and antagonization of the low molecular weight heparin CY 216 in man. Thromb Res. 1986;44:549-554.
8. Herbert JM, Maffrand JP. Heparin interactions with cultured human vascular endothelial and smooth muscle cells: incidence on vascular smooth muscle cell proliferation. J Cell Physiol. 1989;138: 424-432.
9. Hanke H, Oberhoff M, Hanke S, Hassenstein S, Kamenz J, Schmid KM, Betz E, Karsch KR. Inhibition of cellular proliferation after experimental balloon angioplasty by low-molecular weight heparin. Circulation. 1992;85:1548-1556.
10. Castellot JJ Jr, Wright TC, Karnowsky MJ. Regulation of vascular smooth muscle cell growth by heparin and heparan sulfates. Semin Thromb Hemost. 1987;13:489-453.
11. Hanke H, Strohschneider T, Oberhoff M, Betz E, Karsch KR. Time course of smooth muscle cell proliferation in the intima and media of arteries following experimental angioplasty. Circ Res. 1990;67: 651-659.
12. Kakuta T, Currier JW, Haudenschild CC, Ryan TJ, Faxon DP. Differences in compensatory vessel enlargement, not neointimal formation, account for restenosis following angioplasty in the hypercholesterolemic rabbit model. Circulation. 1994;89:2809-2815.
13. Ellis SG, Roubin GS, Wilentz J, Douglas JS, King SB. Effect of 18-24 hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty. Am Heart J. 1989;117:777-782.
14. Brack MJ, Ray S, Chauhan A, Fox J, Hubner PJB, Schofield P, Harley A, Gerschlick AH, for the SHARP Investigators. The Subcutaneous Heparin and Angioplasty Restenosis Prevention (SHARP) trial: results of a multicenter randomized trial investigating the effects of high dose unfractionated heparin on angiographic restenosis and clinical outcome. J Am Coll Cardiol. 1995; 26:947-954.
15. Faxon DP, Spiro TE, Minor S, Coté G, Douglas J, Gottleib R, Califf R, Dorosti K, Topol E, Gordon JB, Ohmen M, and the ERA Investigators. Low molecular weight heparin in prevention of restenosis after angioplasty: results of Enoxaparin Restenosis (ERA) trial. Circulation. 1994;90:908-914.
16. Cairns JA, Gill G, Morton B, Roberts R, Gent M, Hirsh J, Holder D, Finnie K, Marquis JF, Naqvi S, Cohen E. Fish oils and low-molecular-weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty: the EMPAR study. Circulation. 1996;94:1553-1560.
17. Karsch KR, Preisack MB, Baildon R, Eschenfelder V, Foley D, Garcia EJ, Kaltenbach M, Meisner C, Selbmann HK, Serruys PW, Shiu MF, Sujatta M, Bonan R, on behalf of the REDUCE Trial Group. Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty: results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE). J Am Coll Cardiol. 1996;28:1437-1443.
18. The TIMI Study Group. The Thrombolysis in Myocardial Infarction trial. N Engl J Med. 1985;312:932-936.
19. Bertrand ME, Lablanche JM, Bauters C, Leroy F, MacFadden E. Discordant results of visual and quantitative estimates of stenosis severity before and after coronary angioplasty. Cathet Cardiovasc Diagn. 1993;28:1-6.